Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC

Pediatric Blood and Cancer

Volumn 55, Issue 4, 2010, Pages 757-760

  Blouin, Pascale ^a   Yvert, Marion ^a   Arbion, Flavie ^a   Pagnier, Anne ^b   Emile, Jean François ^c   Eitenschenck, Laurence ^b   Machet, Marie Christine ^a   Plantaz, Dominique ^b   Colombat, Philippe ^a   Alla, Corinne Armari ^b   Donadieu, Jean ^d  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

^d ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

2CDA; Aracytine; Juvenile xanthogranuloma; Pancytopenia; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 13A; C REACTIVE PROTEIN; CD163 ANTIGEN; CD68 ANTIGEN; CLADRIBINE; CYTARABINE; ETOPOSIDE; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE; STEROID; VINBLASTINE;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BODY WEIGHT; BONE MARROW BIOPSY; BONE MARROW HYPOPLASIA; CASE REPORT; CELL INFILTRATION; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; ECHOGRAPHY; FEMALE; FULMINATING PURPURA; GROWTH RETARDATION; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HEPATOSPLENOMEGALY; HISTIOCYTE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOALBUMINEMIA; IMMUNOHISTOCHEMISTRY; INFANT; INFECTION; INTRACRANIAL HYPERTENSION; JUVENILE XANTHOGRANULOMA; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MENINGOENCEPHALITIS; MONOCYTE; NEISSERIA MENINGITIDIS; NEUTROPHIL COUNT; PALLOR; PANCYTOPENIA; PAPULE; PHYSICAL EXAMINATION; PNEUMONIA; PRIORITY JOURNAL; ROTHIA MUCILAGINOSA; SEPTICEMIA; SKIN BIOPSY; SKIN DEFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; DRUG COMBINATION; REVIEW;

CLADRIBINE; CYTARABINE; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFANT; MALE; XANTHOGRANULOMA, JUVENILE;

EID: 77957056627     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22629     Document Type: Article

References (13)

1. Freyer DR, Kennedy R, Bostrom BC, et al. Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications. J Pediatr 1996; 129: 227-237.
2. Stover DG, Alapati S, Regueira O, et al. Treatment of juvenile xanthogranuloma. Pediatr Blood Cancer 2008; 51: 130-133.
3. Chantorn R, Wisuthsarewong W, Aanpreung P, et al. Severe congenital systemic juvenile xanthogranuloma in monozygotic twins. Pediatr Dermatol 2008; 25: 470-473.
4. Chantranuwat C. Systemic form of juvenile xanthogranuloma: Report of a case with liver and bone marrow involvement. Pediatr Dev Pathol 2004; 7: 646-648.
5. Hara T, Ohga S, Hattori S, et al. Prolonged severe pancytopenia preceding the cutaneous lesions of juvenile xanthogranuloma. Pediatr Blood Cancer 2006; 47: 103-106.
6. Hu WK, Gilliam AC, Wiersma SR, et al. Fatal congenital systemic juvenile xanthogranuloma with liver failure. Pediatr Dev Pathol 2004; 7: 71-76.
7. Janssen D, Harms D. Juvenile xanthogranuloma in childhood and adolescence: A clinicopathologic study of 129 patients from the Kiel Pediatric Tumor Registry. Am J Surg Pathol 2005; 29: 21-28.
8. Kesserwan C, Boue DR, Kahwash SB. Isolated juvenile xanthogranuloma in the bone marrow: Report of a case and review of the literature. Pediatr Dev Pathol 2007; 10: 161-164.
9. Weitzman S, Jaffe R. Uncommon histiocytic disorders: The non-Langerhans cell histiocytoses. Pediatr Blood Cancer 2005; 45: 256-264.
10. Dehner LP. Juvenile xanthogranulomas in the first two decades of life: A clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003; 27: 579-593.
11. Favara BE, Jaffe R, Egeler RM. Macrophage activation and hemophagocytic syndrome in Langerhans cell histiocytosis: Report of 30 cases 259. Pediatr Dev Pathol 2002; 5: 130-140.
12. Orsey A, Paessler M, Lange BJ, et al. Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 2008; 50: 927-930.
13. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41: 2682-2689.